MX2022006403A - Metodos de tratamiento de hipertension de la arteria pulmonar. - Google Patents
Metodos de tratamiento de hipertension de la arteria pulmonar.Info
- Publication number
- MX2022006403A MX2022006403A MX2022006403A MX2022006403A MX2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A MX 2022006403 A MX2022006403 A MX 2022006403A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- arterial hypertension
- pulmonary arterial
- treating pulmonary
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962941910P | 2019-11-29 | 2019-11-29 | |
| US202063023452P | 2020-05-12 | 2020-05-12 | |
| US202063076149P | 2020-09-09 | 2020-09-09 | |
| PCT/EP2020/083593 WO2021105331A1 (en) | 2019-11-29 | 2020-11-27 | Methods of treating pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006403A true MX2022006403A (es) | 2022-08-25 |
Family
ID=73726769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006403A MX2022006403A (es) | 2019-11-29 | 2020-11-27 | Metodos de tratamiento de hipertension de la arteria pulmonar. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12485119B2 (https=) |
| EP (1) | EP4065119B1 (https=) |
| JP (3) | JP7721520B2 (https=) |
| KR (1) | KR20220106974A (https=) |
| CN (1) | CN114728002A (https=) |
| AU (1) | AU2020392424A1 (https=) |
| BR (1) | BR112022010311A2 (https=) |
| CA (1) | CA3158292A1 (https=) |
| CR (1) | CR20220305A (https=) |
| EC (1) | ECSP22051163A (https=) |
| ES (1) | ES2994089T3 (https=) |
| IL (1) | IL293271A (https=) |
| JO (1) | JOP20220127A1 (https=) |
| MX (1) | MX2022006403A (https=) |
| PE (1) | PE20221320A1 (https=) |
| PH (1) | PH12022551294A1 (https=) |
| TW (1) | TW202133851A (https=) |
| WO (1) | WO2021105331A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024099953A1 (en) * | 2022-11-07 | 2024-05-16 | Actelion Pharmaceuticals Ltd | Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension |
| KR102663470B1 (ko) * | 2023-03-16 | 2024-05-10 | 주식회사 케어사이드 | 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002227984B8 (en) | 2000-12-18 | 2007-01-04 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
| TWI316055B (https=) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| JP5764061B2 (ja) | 2008-08-13 | 2015-08-12 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | マシテンタン含有治療用組成物 |
| LT2447254T (lt) | 2009-06-26 | 2018-01-10 | Nippon Shinyaku Co., Ltd. | Kristalai |
| WO2011024874A1 (ja) | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| MX346730B (es) | 2010-10-15 | 2017-03-30 | Gilead Sciences Inc | Composiciones y metodos para el tratamiento de la hipertension pulmonar. |
| EP3136101B1 (en) | 2014-04-22 | 2019-12-25 | Tohoku University | Method of testing for pulmonary hypertension |
| CN107427698A (zh) | 2015-01-13 | 2017-12-01 | 维瓦斯公司 | 肺高血压的组合疗法 |
| CA3041679A1 (en) | 2016-10-27 | 2018-05-03 | Lawrence S. ZISMAN | Combination therapy for treating pulmonary hypertension |
| PT3897646T (pt) * | 2018-12-21 | 2024-07-08 | Actelion Pharmaceuticals Ltd | Macitentano para tratamento de hipertensão arterial pulmonar |
-
2020
- 2020-11-27 CA CA3158292A patent/CA3158292A1/en active Pending
- 2020-11-27 AU AU2020392424A patent/AU2020392424A1/en not_active Abandoned
- 2020-11-27 KR KR1020227017465A patent/KR20220106974A/ko active Pending
- 2020-11-27 CR CR20220305A patent/CR20220305A/es unknown
- 2020-11-27 BR BR112022010311A patent/BR112022010311A2/pt not_active IP Right Cessation
- 2020-11-27 US US17/780,064 patent/US12485119B2/en active Active
- 2020-11-27 ES ES20820054T patent/ES2994089T3/es active Active
- 2020-11-27 WO PCT/EP2020/083593 patent/WO2021105331A1/en not_active Ceased
- 2020-11-27 JP JP2022531531A patent/JP7721520B2/ja active Active
- 2020-11-27 TW TW109141697A patent/TW202133851A/zh unknown
- 2020-11-27 MX MX2022006403A patent/MX2022006403A/es unknown
- 2020-11-27 CN CN202080081138.2A patent/CN114728002A/zh active Pending
- 2020-11-27 PE PE2022000799A patent/PE20221320A1/es unknown
- 2020-11-27 JO JOP/2022/0127A patent/JOP20220127A1/ar unknown
- 2020-11-27 IL IL293271A patent/IL293271A/en unknown
- 2020-11-27 EP EP20820054.3A patent/EP4065119B1/en not_active Revoked
- 2020-11-27 PH PH1/2022/551294A patent/PH12022551294A1/en unknown
-
2022
- 2022-06-28 EC ECSENADI202251163A patent/ECSP22051163A/es unknown
-
2024
- 2024-07-24 JP JP2024118344A patent/JP7620758B2/ja active Active
-
2025
- 2025-07-30 JP JP2025127467A patent/JP2025172745A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220305A (es) | 2022-07-28 |
| BR112022010311A2 (pt) | 2022-08-16 |
| PH12022551294A1 (en) | 2023-11-20 |
| KR20220106974A (ko) | 2022-08-01 |
| PE20221320A1 (es) | 2022-09-08 |
| US20230032813A1 (en) | 2023-02-02 |
| JP7721520B2 (ja) | 2025-08-12 |
| JP7620758B2 (ja) | 2025-01-23 |
| JP2023504115A (ja) | 2023-02-01 |
| EP4065119B1 (en) | 2024-09-04 |
| AU2020392424A1 (en) | 2022-06-02 |
| JOP20220127A1 (ar) | 2023-01-30 |
| ES2994089T3 (en) | 2025-01-17 |
| EP4065119A1 (en) | 2022-10-05 |
| WO2021105331A1 (en) | 2021-06-03 |
| JP2024153734A (ja) | 2024-10-29 |
| CN114728002A (zh) | 2022-07-08 |
| TW202133851A (zh) | 2021-09-16 |
| IL293271A (en) | 2022-07-01 |
| ECSP22051163A (es) | 2022-07-29 |
| JP2025172745A (ja) | 2025-11-26 |
| CA3158292A1 (en) | 2021-06-03 |
| US12485119B2 (en) | 2025-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007002311A (es) | Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos. | |
| MY158162A (en) | 5-membered heterocycle-based p38 kinase inhibitors | |
| MX2020009773A (es) | Terapia de combinacion. | |
| SI3972603T1 (sl) | Postopki zdravljenja sjogrenovega sindroma z uporabo zaviralca brutonove tirozin kinaze | |
| MX2023010064A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| PH12022551294A1 (en) | Methods of treating pulmonary arterial hypertension | |
| WO2005030187A3 (en) | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension | |
| PE20210096A1 (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| ATE363907T1 (de) | Verfahren zur behandlung von multipler sklerose | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| MXPA05011858A (es) | Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico. | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| PH12021551180A1 (en) | Methods of treating myeloproliferative disorders | |
| NO20054371L (no) | Somatostatin-dopamin kimaere analoger | |
| ZA201907101B (en) | Methods of preventing or treating ophthalmic diseases | |
| MX2021000094A (es) | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. | |
| ZA202101055B (en) | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors | |
| EP3968985A4 (en) | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors | |
| EA200500427A1 (ru) | Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями | |
| TW200621261A (en) | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof | |
| MX2025002392A (es) | Formulaciones de dantroleno y metodos de uso de dichas formulaciones | |
| MX2021014705A (es) | Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento. | |
| MX2026000635A (es) | Antagonistas del canal de potasio kv1.3 | |
| AU2003219199A1 (en) | Use of an alfa2-adrenoreceptor antagonist for cns-related diseases |